Innovative Pulmonary Rehabilitation Telehealth Program for Improving COPD Patient Outcomes
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Kansas
-
Kansas City, Kansas, United States, 66160
- University of Kansas Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Hospital discharge diagnosis of COPD
- Spirometry-confirmed evidence of COPD Global Initiative for Chronic Obstructive Lung Disease (GOLD) stages I to IV
- Access to internet connection and knowledge on use of web-based programs
Exclusion Criteria:
- Persons with additional significant comorbidities including cancer, cardiac disease and physical impairments
- Non-English speaking persons
- The inability to provide an informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: COPD Telehealth Program
Participants will take part in a structured telehealth program for 12 weeks.
Web-based educational tools will be made available to participants.
Study participants will meet with a registered respiratory therapist two times per week.
|
Telehealth program delivered remotely to study participants.
Program developed by Cambium Technologies.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Measure of physical activity
Time Frame: Change from Baseline to Week 12
|
Changes will be measured using the Yale Physical Activity Survey (YPAS).
The tool is composed of two sections - (a) amount of physical activity/exercise performed during a typical week in the past month and (b) activities performed in the past month.
The final index score is the sum of five individual indices (vigorous, leisurely walking, moving, standing and sitting).
Scores on the scale range from 0 to 137.
The higher the score the more active a person.
|
Change from Baseline to Week 12
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Quality of Life
Time Frame: Change from Baseline to Week 12
|
The COPD Assessment Test (CAT) will be used to measure the health status of the subjects.
The test has eight questions.
Each question has a range from 0-5.
The total score for the test ranges from 0 to 40.
The higher the score the more severe a person's COPD.
|
Change from Baseline to Week 12
|
|
Adherence to physical activity requirements
Time Frame: Week 12
|
Patients receive an individualized exercise plan (minutes and days per week).
Adherence to physical activity is assessed by the proportion of weeks subjects achieve their planned physical activity time.
|
Week 12
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Cheryl Skinner, RRT, CPFT, University of Kansas Medical Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- STUDY00141490
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COPD
-
NCT07361653Not yet recruitingCOPD | Lung Disease, Chronic Obstructive | COPD Patients | COPD Acute Exacerbation | COPD (Chronic Obstructive Pulmonary Disease) | Lung Disease Airways | COPD Exacerbations
-
NCT07031440Not yet recruiting
-
NCT06252818Recruiting
-
NCT06199258Recruiting
-
NCT04715659Recruiting
Clinical Trials on Telehealth Program
-
NCT07001241RecruitingBreast Cancer | Prostate Cancer | Cancer-related Fatigue
-
NCT04783532TerminatedPain | Back Pain | Low Back Pain | Chronic Low-back Pain
-
NCT06033924RecruitingPeripheral Artery Disease
-
NCT04423653UnknownTelemedicine | Cerebral Palsy, Spastic
-
NCT01724684UnknownChronic Obstructive Pulmonary Disease
-
NCT05810675RecruitingAutism Spectrum Disorder
-
NCT07445802Not yet recruitingTreatment Adherence and Compliance | Bipolar Disorder (BD) | Severe Mental Disorders | Schizophrenia Disorder
-
NCT04855552Active, not recruitingBody Weight | Overweight and Obesity | Cancer of Breast | Cancer Survivors
-
NCT04495686Active, not recruitingAlzheimer Disease | Traumatic Brain Injury | Dementia, Mixed | Dementia Mild | Dementia Moderate